NewAmsterdam Pharma (NASDAQ:NAMS) Reaches New 52-Week High – Should You Buy?

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) reached a new 52-week high on Monday . The company traded as high as $42.21 and last traded at $41.59, with a volume of 528706 shares traded. The stock had previously closed at $38.73.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on NAMS shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. Guggenheim upped their price target on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Royal Bank Of Canada upped their price target on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, HC Wainwright raised shares of NewAmsterdam Pharma to a “strong-buy” rating in a research note on Thursday, February 19th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $48.00.

NewAmsterdam Pharma Stock Down 2.9%

The stock has a market capitalization of $4.34 billion, a price-to-earnings ratio of -21.09 and a beta of 0.02. The company’s 50-day simple moving average is $32.02 and its 200 day simple moving average is $34.30.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. The business had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. On average, equities analysts expect that NewAmsterdam Pharma Company N.V. will post -1.76 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CEO Michael H. Davidson sold 443,707 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the transaction, the chief executive officer directly owned 174,144 shares of the company’s stock, valued at $5,790,288. This represents a 71.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Johannes Jacob Piete Kastelein sold 104,467 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $30.30, for a total transaction of $3,165,350.10. Following the transaction, the insider directly owned 69,302 shares in the company, valued at $2,099,850.60. The trade was a 60.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 1,168,286 shares of company stock valued at $38,211,967 over the last three months. 12.74% of the stock is currently owned by insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds have recently bought and sold shares of the business. Farther Finance Advisors LLC grew its position in shares of NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after purchasing an additional 708 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares during the last quarter. KBC Group NV acquired a new stake in shares of NewAmsterdam Pharma in the first quarter valued at about $37,000. Navalign LLC bought a new stake in NewAmsterdam Pharma during the 4th quarter valued at approximately $46,000. Finally, Wolverine Asset Management LLC bought a new stake in NewAmsterdam Pharma during the 3rd quarter valued at approximately $69,000. 89.89% of the stock is owned by institutional investors and hedge funds.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.